Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.44 |
| ▸ | BACE1 | P56817 | 4/20 | 0.40 |
| ▸ | BMP1 | P13497 | 3/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5109335 | 0.92 | NPSR1 (0.42) | PTGDR2BACE1BMP1NPSR1SMN1; SMN2 | |
| SCHEMBL5109967 | 0.90 | PTGDR2 (0.44) | PTGDR2NPSR1SMN1; SMN2LMNAMAPT | |
| SCHEMBL5113142 | 0.86 | NR1I2 (0.40) | PTGDR2BACE1NPSR1SMN1; SMN2LMNA | |
| SCHEMBL5120798 | 0.85 | PTGDR2 (0.59) | PTGDR2NPSR1SMN1; SMN2LMNAMAPT | |
| SCHEMBL5112502 | 0.84 | NPSR1 (0.42) | PTGDR2NPSR1SMN1; SMN2LMNAMAPT | |
| SCHEMBL5120697 | 0.84 | PTGDR2 (0.38) | PTGDR2BACE1NPSR1SMN1; SMN2LMNA | |
| SCHEMBL5114774 | 0.83 | PTGDR2 (0.47) | PTGDR2NPSR1SMN1; SMN2LMNAMAPT | |
| SCHEMBL5114024 | 0.83 | PTGDR2 (0.45) | PTGDR2NPSR1SMN1; SMN2LMNAMAPT | |
| SCHEMBL5122394 | 0.82 | PTGDR2 (0.46) | PTGDR2NPSR1SMN1; SMN2LMNAMAPT | |
| SCHEMBL5107629 | 0.82 | PTGDR2 (0.46) | PTGDR2NPSR1SMN1; SMN2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273740-B2 | antiallergen; not direct way to change nature of immunological response to allergen; G-protein-coupled \"chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2)\" antagonist for prostaglandin PGD2, that mediates PGD2-dependent migration of blood Th2 cells; ; asthma, rhinitis, COPD | ACTELION PHARMACEUTICALS, LTD. (CH) | 2012-09-25 | — | — | US | disclosed |
| US-20080108638-A1 | 2-Sulfanyl-Benzoimidazol-1-Yl-Acetic Acid Derivatives as Crth2 Antagonists | ACTELION PHARMACEUTICALS,LTD. (CH) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108638-A1 | 2-Sulfanyl-Benzoimidazol-1-Yl-Acetic Acid Derivatives as Crth2 Antagonists | HRH2, HRH1, HRH3 | PTGDR2 12/4885BACE1 3635/4885BMP1 3150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.